1910 studies found for:    Lipid Storage Diseases
Show Display Options
Rank Status Study
21 Completed Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia
Condition: Lipid Metabolism Disorder
Intervention: Drug: ezetimibe
22 Completed
Has Results
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
23 Active, not recruiting An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
24 Completed
Has Results
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: mipomersen;   Drug: Placebo
25 Completed Regulation of Lipoprotein Transport in Metabolic Syndrome
Conditions: Obesity;   Lipid Disorders;   Cardiovascular Disease
Interventions: Drug: GW501516;   Drug: placebo pill
26 Completed Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
Conditions: Lipid Metabolism, Inborn Errors;   Hyperlipidemias;   Metabolic Diseases;   Hypolipoproteinemia;   Hypolipoproteinemias;   Hypobetalipoproteinemias;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Congenital Abnormalities;   Metabolic Disorder;   Hypercholesterolemia;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: ISIS 301012 (mipomersen)  sodium;   Drug: Placebo;   Drug: ISIS 301012 (mipomersen) sodium;   Drug: placebo;   Drug: ISIS 301012 (mipomersen)   sodium
27 Completed A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 in Subjects With Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemias;   Hyperlipidemias;   Lipid Metabolism Disorders;   Metabolic Diseases
Intervention: Biological: PF-04950615
28 Recruiting Influence of Caloric Restriction and Resveratrol in the Sirtuin System in Women and Men Aged 55 to 65 Years
Conditions: Vascular System Injuries;   Lipid Metabolism Disorders;   Endothelial Disfunction
Interventions: Drug: Resveratrol;   Behavioral: Caloric restriction
29 Completed
Has Results
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
Conditions: Metabolic Diseases;   Hyperlipidemias;   Metabolic Disorder;   Hypercholesterolemia;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: mipomersen;   Drug: placebo
30 Recruiting Alpha-linolenic Acid and Blood Pressure
Conditions: Hypertension;   Lipid Metabolism Disorders
Interventions: Dietary Supplement: Flaxseed oil;   Dietary Supplement: high oleic sunflower oil (HOSF)
31 Active, not recruiting Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
Conditions: Hyperlipidemias;   Hypertriglyceridemia;   Dyslipidemias;   Lipid Metabolism Disorders;   Metabolic Diseases
Interventions: Drug: CAT-2003;   Drug: Placebo
32 Active, not recruiting Multiple Treatment Study
Condition: Body Fat Disorder
Intervention: Device: The Zeltiq System
33 Recruiting Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Conditions: Mucopolysaccharidosis;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux-Lamy Syndrome;   Sly Syndrome;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy (ALD);   Krabbe Disease;   Metachromatic Leukodystrophy (MLD);   Sphingolipidoses;   Peroxisomal Disorders
Interventions: Drug: Campath-1H;   Drug: Cyclophosphamide;   Drug: Busulfan;   Procedure: Allogeneic stem cell transplantation;   Drug: Cyclosporine A;   Drug: Mycophenolate Mofetil
34 Active, not recruiting Non-Invasive Reduction of Fat in the Inner Thighs
Condition: Body Fat Disorder
Intervention: Device: The Zeltiq System
35 Recruiting Outer Thigh Study With Varied Treatment Parameters
Condition: Body Fat Disorder
Intervention: Device: The Zeltiq System
36 Completed Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature
Condition: Body Fat Disorder
Intervention: Device: The Zeltiq System
37 Active, not recruiting Feasibility Study of a Belt Applicator
Condition: Body Fat Disorder
Intervention: Device: The Zeltiq System
38 Recruiting Colder Flank Study
Condition: Body Fat Disorder
Intervention: Device: The Zeltiq System
39 Completed Clinical Trial of Transtek Body Fat Analyzer (GBF-1251-B & Other 3 Models)
Conditions: Weight;   Body Fat Disorder;   Bone Mass
Interventions: Device: Transtek 125X;   Device: Transtek 950D
40 Unknown  Pilot Study of CoolTXT for Non-Invasive Fat Reduction
Condition: Body Fat Disorder
Intervention: Device: The Zeltiq System

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years